Therapeutic targeting of osteoclast function and pathways.
about
The study of mechanisms of protective effect of Rg1 against arthritis by inhibiting osteoclast differentiation and maturation in CIA miceNorisoboldine suppresses osteoclast differentiation through preventing the accumulation of TRAF6-TAK1 complexes and activation of MAPKs/NF-κB/c-Fos/NFATc1 PathwaysTotal saponin from Anemone flaccida Fr. Schmidt abrogates osteoclast differentiation and bone resorption via the inhibition of RANKL-induced NF-κB, JNK and p38 MAPKs activationTartrate-Resistant Acid Phosphatase 5b is a Useful Serum Marker for Diagnosis and Recurrence Detection of Giant Cell Tumor of Bone.Aconine inhibits RANKL-induced osteoclast differentiation in RAW264.7 cells by suppressing NF-κB and NFATc1 activation and DC-STAMP expression.A novel pyrazole derivative protects from ovariectomy-induced osteoporosis through the inhibition of NADPH oxidase.Giant-cell tumor of bone, anti-RANKL therapy.Osteoclast differentiation inhibitors: a patent review (2008 - 2012).RETRACTED: Establishing an osteosarcoma associated protein-protein interaction network to explore the pathogenesis of osteosarcoma.Baicalein induces human osteosarcoma cell line MG-63 apoptosis via ROS-induced BNIP3 expression.Norisoboldine alleviates joint destruction in rats with adjuvant-induced arthritis by reducing RANKL, IL-6, PGE(2), and MMP-13 expression.Ferulic acid impairs osteoclast fusion and exacerbates survival of mature osteoclasts.A vitronectin-derived peptide reverses ovariectomy-induced bone loss via regulation of osteoblast and osteoclast differentiation.Natural polyamines inhibit the migration of preosteoclasts by attenuating Ca2+-PYK2-Src-NFATc1 signaling pathways.Urokinase receptor mediates osteoclastogenesis via M-CSF release from osteoblasts and the c-Fms/PI3K/Akt/NF-κB pathway in osteoclasts.A study on the prevention and treatment of murine calvarial inflammatory osteolysis induced by ultra-high-molecular-weight polyethylene particles with neomangiferin
P2860
Q34152121-D04683C3-930E-4074-98A5-7A02EC56C9BDQ34639619-894E9EAE-EA1B-4B5A-B4FD-8CB0EF7C973AQ35213395-AC3445AF-438C-49DB-B143-74491CB4F4ABQ36212068-622DFCC2-A065-4855-96E4-A5E5570E43DBQ36579296-C70ACC0E-39A1-4E45-BFD3-2704A9CF1A65Q36687909-9FDE3AD9-B158-4805-87E7-8789F68B115CQ37404945-5807AA55-1361-4C84-8B1E-2CE0EA4B8123Q38149300-77E92818-D171-4484-BAAA-13F4A6029722Q38482145-304D09B6-EFBA-4E7F-90C2-379C3E44F01EQ38916767-829D0234-BC78-4B2C-B53F-3AE728C44028Q39014536-C33DAC98-21DF-4D95-B77A-E0FAD089C6C3Q41639542-71441136-C7DC-43AF-926E-F7775D47F60FQ49925395-A97D980F-B017-40D3-B039-CB6D823DC33CQ54322773-5ECEE1AB-2F35-4161-84CC-55B774D68D42Q54324442-DFB5721E-C7A3-4A90-8E83-2BF3178CCBF9Q58552574-2AB81CE1-D15F-4EF5-988C-6E737542D52A
P2860
Therapeutic targeting of osteoclast function and pathways.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 05 January 2011
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Therapeutic targeting of osteoclast function and pathways.
@en
Therapeutic targeting of osteoclast function and pathways.
@nl
type
label
Therapeutic targeting of osteoclast function and pathways.
@en
Therapeutic targeting of osteoclast function and pathways.
@nl
prefLabel
Therapeutic targeting of osteoclast function and pathways.
@en
Therapeutic targeting of osteoclast function and pathways.
@nl
P2093
P2860
P1476
Therapeutic targeting of osteoclast function and pathways
@en
P2093
Crispin R Dass
Damian E Myers
Jonathan C M Clark
Matthew L Broadhead
P2860
P304
P356
10.1517/14728222.2011.546351
P407
P577
2011-01-05T00:00:00Z